FDA approves Dupixent for moderate-to-severe atopic dermatitis in adolescents

This article was originally published here

Dupixent can be used with or without topical corticosteroids. “For the first time, adolescents with uncontrolled moderate-to-severe atopic dermatitis have an approved biologic treatment option to help control

The post FDA approves Dupixent for moderate-to-severe atopic dermatitis in adolescents appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply